Dupilumab plus tofacitinib for moderate to severe eczema
Treatments studied
Part of Genetic & congenital, Immune system & allergy, Skin clinical trials.
This study tests whether combining two drugs, dupilumab and tofacitinib, works better for moderate to severe eczema in adults than either alone. It may help people whose eczema is not well controlled with standard treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 60 years old.
- You have had eczema (atopic dermatitis) for at least 6 months, and it is moderate to severe (covers 10% or more of your body and causes significant itching).
- You have not used dupilumab in the last 6 weeks, and you have not used other JAK inhibitors (like Rinvoq or Xeljanz) in the past month.
- You are not pregnant, breastfeeding, or planning to become pregnant, and you are willing to use effective birth control during the study and for 3 months after.
- You do not have active infections (like tuberculosis, hepatitis, or shingles), a history of blood clots, or other serious health issues (like recent heart problems or cancer).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests if a pill called upadacitinib (a JAK inhibitor) can help adults with moderate-to-severe atopic dermatitis (eczema) that didn't improve enough with dupilumab. You may be able to join if your eczema is still active despite using dupilumab for at least 4 months.
This study tests whether an oral medicine (upadacitinib) works as well as a shot (dupilumab) for children aged 2 to 12 with moderate to severe eczema. It aims to see which treatment better controls symptoms like itching and skin rashes.
This study compares a new injectable medicine (IBI3027) to an approved one (Dupilumab) for people with moderate-to-severe eczema. If you join, you'll receive one of the two treatments to see if the new one works as well for reducing itching and skin symptoms.
This study looks at how well dupilumab works for children and teens with severe eczema (atopic dermatitis) even when the rash is not widespread. It aims to see if the treatment helps with itching, quality of life, and rashes in visible or sensitive areas.
This study tests a new medication called IBI356 for people with moderate to severe eczema that hasn't improved with standard creams. The goal is to see if this medicine can safely reduce the redness, itching, and rash.
This study tests a new medication called IBI3002 for people with moderate to severe eczema (atopic dermatitis) that hasn't been well controlled by standard creams. The goal is to see if IBI3002 can reduce skin inflammation and itching.
Hear when a new Atopic Dermatitis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.